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Economic Aspects of Peripheral Arterial Disease
The general purpose of an economic evaluation in the field of health care is to relate the costs of a
diagnostic or therapeutic strategy to its outcomes. The two components of the evaluation are thus
a measure of effectivenessand an estimate of costs. Economic evaluation is currently both a deci-
sion tool and an evolving academic discipline.Ls Thus, existing guidelines reflect the current state
of the art but are subject to alterations when new methodological tools become available.3,4 ,5 The
following discussion and recommendations relate to the interpretation and design of specialized
expert studies aimed at identifying, as accurately as possible, the economic implications of medical
procedures. It is of course not intended that these detailed considerations necessarily apply to all
clinical studies.
Perspective in Economics
The fundamental principle is that the figure chosen to estimate the cost of given goods or a ser-
vice will depend on the viewpoint chosen; there is no "right" figure, but rather calculations
must be made consistently. From the viewpoint of the patient, relevant costs are all of the out-
of-pocket expenses. This includes, for instance, nonreimbursed medical fees and drug costs plus
non-health care costs such as extra help in the household or alterations for an amputee that are
not covered by insurance or social benefits. From the viewpoint of the hospital, personnel,
equipment, supplies, capital, and overhead in the hospital are relevant. The chosen viewpoint
can affect the results profoundly. For example, the mean costs of treating a severe contrast reac-
tion were found to be $15 (Euro 14) from the perspective of the radiology department, $910
(Euro 846) from the perspective of the hospital, and $3,103 (Euro 2,886) for the third-party
payer. 6 Similarly, the chairman of a medical, surgical, or technical department is usually
accountable for personnel, equipment, maintenance, and supplies in his or her own department
but may not consider costs borne by other departments." The health care system consider all
medical costs but not social costs, and the insurer will consider total payment made to health
care providers.v-f The most encompassing viewpoint is society's and is recommended in current
guidelines, although it involves an exhaustive data collection.
Recommendation 6: Perspective in economic evaluation of peripheral arterial disease
It is important to collect cost and outcome data related to the diagnosis and treatment
of peripheral arterial disease. Current guidelines recommend that the overall societal
perspective be taken to compute the costs and effectiveness.
General Principles of Economic Evaluation
Economic evaluation from the societal viewpoint requires the following;
• The time horizon for the computation of costs and benefits must be defined: that is, the
time over which the consequences of the strategy are likely to extend.
• The case-type or the population chosen for the assessment of costs and benefits must be
defined: the cost of a procedure will depend, for instance, on the severity of the underlying
disease or the frailty of the patient. When economic analysis is undertaken alongside clinical
trials, costs data are usually collected on all of the patients included. An economic evalua-
tion performed retrospectively or with a model requires decisions about which patients'
data will be used to derive costs and benefits.
• The type of health care facility must be defined: the costs are different from one facility to
another (and from one country to another). Factors of variation include the type of equip-
ment, the quality of maintenance, the number of patients and the ability of the operators.
Optimally, economic assessment would be performed in institutions that are familiarwith
the treatment of a given disease.
• The comparator for the strategy under evaluation should be defined.
• Costs estimated from the societal viewpoint should include both health care and
non-health care costs.
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Cost computations can use data collected either prospectively or retrospectively. The advantages
and disadvantages for each design are the same as in clinical studies. The distribution of cost
data is usually skewed because of outliers. Sensitivity analyses are useful when the data used in
the baseline analysis are uncertain or likely to change in a different setting. The sensitivity analy-
ses explore the changes in the final result that occur when the assumptions used in the baseline
calculations are challenged. For example, the value for effectiveness varies within its confidence
interval.
Recommendation 7: Method of cost data collection
• Similar to clinical data, cost data ideally should be collected prospectively.
• Sensitivity analysis should be used to consider the uncertainty in both the effective -
ness and the cost data. An important step in a cost-effectiveness analysis is the 'what
ill' analysis, or sensitivity analysis. To analyze the effect of uncertainty in the esti-
mated parameters, the uncertain variable is varied over the range of values consid-
ered plausible and the effect on the decision determined.
• Prospective randomized controlled trials are considered the optimal form of
assessment.
• The cost of a given strategy should be computed on an intent-to-treat basis. In other
words, the costs of cross-over patients are attributed to the strategy to which they
were initially randomized.
All costs and charges calculated in past studies should be updated. The adjustment to current
value can be made either with the country's inflation rate estimated by the consumer price
index, or preferably by the medical inflation rate, that is, the rate of increase in the price of med-
ical goods and services.! Between-country comparison of costs should ideally use purchasing
power parity. When computing total costs from a societal viewpoint, logic dictates to aggregate
medical (hospital and ambulatory) and social (tangible and intangible) costs. Decision-makers,
however, tend to be skeptical about this method, because budgets are separated, sometimes very
effectively, so that money saved for ambulatory patients will not benefit hospitals. Similarly,
non-health care money saved by a shorter length of stay, which reduces the number of work-
days lost, will not be transferred to the health care system. This illustrates one of the limits of
economic evaluation as a tool for decision making. 9,10,1l ,12
Computation of Costs
There are many components to the "global" cost of a diagnostic or therapeutic strategy. Ideally,
decision makers should consider all of them before making a decision regarding which are rele-
vant from a given viewpoint. Costs are different from charges (or fees), which represent the bill
(given to the patient or the payer). Costs are, by definition, the value of resources that were
committed to one particular use, and therefore the opportunity to use them elsewhere is fore-
gone. Ideally, one would want to perform a full cost accounting study, including a measure of
time (ie, time needed to perform a particular task) to estimate the actual workload for nurses
and doctors in a given case-type. American authors commonly report COSt estimates based on
charges adjusted with cost-to-charge ratios specific for the insurer, hospital, or department and
for the fiscal year. In Europe, where no such tool exists, authors either use the hospital billing
data, which is not considered an accurate estimate of costs, or cost accounting data. Both costs
from within the health care system.and nonhealth costs are considered. Costs considered in an
economic analysis are tangible and intangible, positive and negative (avoided). The cost of a
strategy is the sum of all costs related directly or indirectly to the procedure, minus all costs
averted.
Health care costsencompass the full extent of the health care system, hospital and ambulatory.
They comprise personnel, equipment, supplies, capital, and overheads. Both immediate costs
and follow-up costs should be included. For example, angioplasty for femoropopliteal arterial
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disease may appear less expensive than surgery when considering the initial procedure, but it
may be more expensive if failure or major complications are included. The costs of intervention-
al treatment for claudication were documented by Hunink et all 3,14 in the case of both angio-
plasty and bypass surgery. These costs are lower than those found for the same procedures in
patients with critical limb ischemia. Costs for a single angioplasty procedure are lower than costs
for bypass, in part because of the differing severity of the underlying arterial disease. The
authors found average hospital costs of $6,152 ± $3,243 (Euro 5,721) and $11,582 ± $5,624
(Euro 10,771) for primary uncomplicated angioplasty and bypass, respectively. A recent study
documented an average cost of $9,365 ± 4,366 (Euro 8,709) tor fernoropopliteal PTA, versus
$15,470 ± 7,585 (Euro 14,387) for femoropopliteal bypass.lf The corresponding costs adjusted
to a reference patient population (51- to 70-year-old men with claudication and no procedure-
related complications) were $6,500 for femoropopliteal PTA and $12,500 for femoropopliteal
bypass. (See Costs of Treatment for Critical Limb Ischemia, D 5.1.2, p 5275.)
Tangible non-health care costs represent lost productivity (because of absence from work at the
time of treatment or during recovery, or reduced productivity at work) by the patient and his or
her family, Other tangible non-health care costs include expenses such as transportation, child
care, home help, or alterations in the home rendered necessary by, for example, an amputation.
The time cost is estimated by the opportunity cost of the actual time spent getting a diagnosis
and treatment. Opportunity costs represent the value of outcomes that were not achieved because
resources were committed to another use. For example, the opportunity cost of the time spent
by a patient in obtaining treatment is the amount of money that he or she could have gained by
performing other tasks. These costs can be estimated by current market wage rates.16,17 This
may be of importance when considering the costs to the patient of a supervised exercise pro-
gram. The value of lost productivity is derived from the number of days of absence from work
and whether the patient resumed work after treatment. Because many patients with PAD are
older than 65 years and retired, the costs of lost productivity may be considered negligible.
There is controversy about the inclusion in cost calculations of future unrelated health care and
non-health care costs (eg, a patient whose life is prolonged after an intervention for eLI may
develop lung cancer and generate costs for this disease): in the case of treatment for PAD, there
is no evidence that one treatment significantly prolongs life compared with another, and there-
fore future unrelated costs would cancel out in comparisons of therapeutic strategies.
Intangible costs or psychological costs assess tile loss of quality of life resulting from an illness, such
as anxiety and pain, borne by both the patients and the rest of society. These costs cannot be esti-
mated by a market price or the value of resources used in a production process. A proposed
method used to value tile loss of quality of life is willingness to pay. That is, the amount of money
that a person would be ready to pay to avoid a certain adverse event is the cost attributed to this
event. For example, society may be willing to pay a certain amount to avoid diagnostic angiogra-
phy and replace it by magnetic resonance angiography (MRA). Another method is to exclude
these costs from tile cost computations and include them into the quality of life computation.
Recommendation 8: Type of information to be recorded for estimating costs
• Maintain a record of health care resources used, including:
- hospital days in leU/special care/wards
- procedures both in and out of the hospital
- consultations
- follow-up testing
- pharmaceuticals
- physical therapy, exercise therapy, rehabilitation
• Record the time actually spent by the patient in obtaining health care
• Maintain a record of the duration of absence from work, whether or not work is
resumed. If work is resumed, record at what percentage.
• Record home care resources used, out-of-pocket expenses by patients and family
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For each health care resource fixed, semi-fixed and variable costs should ideally be estimated.
Fixed costs (sometimes referred to as overhead costs) do not vary in the short-term when the
quantity of output produced increases. These costs typically include equipment, building, heat-
ing, lighting, housekeeping, and hospital administrative and information services. Semi-jixed
costs, which increase stepwise when the output increases, are often personnel costs. Variable costs
vary precisely with the level of output, and comprise medical supplies, drugs, films, contrast
media, and maintenance (maintenance can also be a fixed cost if it is not related to heavy use of
equipment). The total cost is the sum of fixed, semi-fixed, and variable costs. In the long term,
by definition, all costs are variable.18
Financial incentives may interfere with the transparency of cost data. When examining the costs of
treatments performed for PAD, the role of financial incentives should not be neglected. Given the
reimbursement schedules used in hospitals, and the possibility of billingpayers differently In some
countries, tile treatments of patients with peripheral vascular disease also may depend on their insur-
ance coverage. For example, in a 1989 study in Long Island (New York), Munoz et al19 found that
tile cost of treating patients in vascular surgery depended not only on tile number of comorbid con-
ditions, but also on the payer. Medicaid patients had an average hospital cost of $7,304 (Euro
6,793), whereasprivate insurance patients had an average cost of $9,537 (Euro 8,869).
The Diagnosis-Related Group (DRG) reimbursement schedule also may create incentives to
perform one procedure rather man another, for example, PTA rather than bypass, which could
result in less than optimal patient management. The incentive for US hospitals to perform PTA
was shown by Kinnison et al,20who compared the hospital charges with the Federal reimburse-
ment for PTA and bypass. In both cases, the hospital charges were less than the Federal reim-
bursement, but the difference was $7,655 (Euro 7,119) per case for PTA versus only $3,081
(Euro 2,865) per case for bypass. In another setting, the inadequacy of the DRG reimburse-
ment system for revascularization procedures was also noted by Gupta and Veith,21 who esti-
mated a mean loss of over $8,000 (Euro 7,440) per patient undergoing successful limb salvage.
A 4.4 Economic Evaluation
A 4.4.1 Types of Economic Evaluations and the Trade-off Between Costs and Effectiveness
Cost minimization analysis
Comparing medical strategies according to two criteria, medical outcome and cost, requires
some form of aggregation. In some cases, one strategy scores better on both outcome and cost
and is therefore a dominant strategy. In other cases, the medical outcome is known to be equiv-
alent across strategies, and a cost minimization analysis suffices.t-'
Cost-effectiveness and cost-utility analysis
Comparison of medical strategies that both use different resources and yield different outcomes
requires a different approach. Cost-effectiveness analyses compare strategies, the costs of which
are expressed in monetary terms while outcomes are expressed in a single medical unit, for
example, lives saved, life years, or quality-adjusted life years. Some authors refer to studies
expressing effectiveness as quality-adjusted lite years as cost-utility analyses.
Cost-benefit analysis
In a cost-benefit analysis, medical outcomes are transformed into monetary units, which requires
expressing the value of a life in terms of dollar costs. The two foremost methods used are the
human capital approach and willingness-to-pay,l,22,23 There is reluctance to do this in practice,
and thus, in health care most economic evaluations are cost-effectiveness analyses. When macro-
economic decisions are considered, cost-benefit analysis is the only type of analysis that allows
comparisons of the benefits of resources committed to different sectors of the economy.
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A differentiation must be made between the terms effectiveness, which means the outcomes of a
strategy under routine clinical conditions, and efficacy, which means the outcomes of a strategy
under the best available conditions of medical and patient management.l,lO,1l,12,24 Most eco-
nomic evaluations of medical therapies or revascularization procedures report data drawn from
trials or cohort studies conducted in major tertiary-care referral centers. Thus, medical out-
comes of these studies are those obtained by highly trained physicians, practicing with standard-
ized methods in a technically favorable environment. Real-life outcomes may be different, given
the heterogeneity of training, practice patterns, and availabilityof equipment. Similar differences
are likely to be found between costs of treatment for patients included in studies and in real life.
This is attributable in part to protocol-driven costs, but also to costs resulting from differences
in compliance on the patient's part and to variation in practice patterns on the physician's part.
Comparing any two strategies yields one of the following four situations: (1) if one strategy
yields greater effectiveness at lower cost than the other strategy, it is superior; (2) ifit yields
lower effectiveness at higher cost, it is inferior; (3) if it yields greater effectiveness at higher cost,
it must be decided whether the incremental costs are worth paying compared to the effective-
ness gained; and (4) if it yields lower effectiveness at lower cost, it must be decided whether the
achieved cost savings are justified compared to the effectiveness lost. A reference strategy, or
"do-nothing" strategy, should always be included, and each strategy should be compared with
its next best strategy. In the case of situations (1) and (2), the decision is straightforward. In sit-
uations (3) and (4), a trade-off needs to be made between costs and effectiveness, and strategies
need to be compared, which is done based on the cost-effectiveness ratio.
The ratio of incremental costs divided by incremental effectiveness, compared with the next best
alternative, is the ratio of interest. A strategy is said to be inferior by dominance if there is
another strategy that is more effective and less costly, and inferior by extended dominance if
there is another strategy that is more effective and has a lower incremental cost-effectiveness
ratio. The final choice among the remaining strategies depends on their incremental cost-effec-
tiveness ratios in comparison with those of other health care programs and on society's willing-
ness to pay.
Reconunendation 9: Use of economic evaluation in peripheral arterial disease
Economic evaluation can provide important information to guide decision-makers in
allocating health care resources. It must be used in association with other important cri-
teria (eg, clinical and quality of life outcomes, available resources).
Limitations of Economic Evaluation in the Current Literature
Compared with the recommendations just stated, the literature on the economics of PAD pre-
sents several limitations:
• Heterogeneous population: Most cost papers report data on a heterogeneous population.
The cost results are attributed to the case-type mat was most prevalent in the study population.
• Comorbid conditions: The description of comorbid conditions such as CAD, chronic
obstructive pulmonary disease, renal insufficiency, and diabetes mellitus, and of postproce
dural complications resulting from these should be part of me description of me popula-
tion. These comorbid conditions add extra costs and possiblyresult in prolonged length of stay.
• Differences between countries: The methods of calculating an economic value for a given
treatment varies between countries .
• Different perspectives in cost computation: The viewpoints chosen for the computation of
cost differ among studies and often reflect the stakes of the authors, in relation to me
financing of their health care systems. Various financial incentives may interfere with the
transparency of cost data. Very few articles attempt a normative computation of costs that
would include hospital, ambulatory, and non-health care costs.
• Different periods of follow-up: The period of observation is another issue as the chronic evo-
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lution of the cl.isease renders follow-up necessary to assess both the recurrent or secondary
costs and the long-term outcomes.
• Use of unsuitable end points: Intermecl.iate end points (duplex fincl.ings or primary patency)
are not considered suitable. End points that can be used in outcomes assessment include:
walking cl.istance and functional status in patients with IC, limb salvage, functional status,
complications in relation to comorbid conditions, and death in CLI patients.
• Use of irrelevant unit of analysis: The relevant unit of analysis is the patient (not the leg),
which is not always the unit used in articles.
Economic evaluations concern both diagnostic and therapeutic strategies. The usefulness of
investigating the coronary or cerebral circulation in patients with arterial cl.isease of the leg has
not been established in relation to its costs. The economic evaluations of diagnostic strategies
often result from decision-analytic models and not from actual trials. These models provide use-
ful information. The necessity of models for clinical and economic outcomes stems from the
requirement, by policy-makers, agencies, and private or public insurers, to obtain data on the
results of a given intervention on the health status of the population and on the costs to the
health care system or to society.25
In the case of cl.iagnostic imaging, modeling is particularly relevant, for at least two reasons: first,
the rapidly evolving technologies and the high costs associated with their use prompt decision-
makers to request estimates of costs and outcomes before large-scale trials have provided results;
second, most outcomes of imaging procedures are intermediate outcomes, and would requi.re
very long follow-up and expensive trials to be converted into health outcomes. It would be of
interest, however, to obtain validation of the existing models with actual patient data.
The following issues concern the evaluation of the costs of treatments:
• The cost of a procedure/of the initial admission for a procedure should be differentiated
from the total cost of a strategy. The notion of total cost cannot be separated from the
notion of time-for how long a follow-up have the costs been computed?-or from the
intention to treat, because the costs of a strategy should be computed on an intention-to-
treat basis.
• Case types must be identified: therapeutic strategies do not always identify clearly the case
types with regard to the severity, the location, and the extension of the peripheral arterial
cl.isease, nor, equally important when costs are concerned, with regard to comorbid condi-
tions. Subgroups of patients with coronary or carotid disease, or with underlying pulmonary
disease, should be separated from healthier patients when cost estimating is performed.
• The setting should be identified: resource use, and therefore costs, also will differ between
countries, depending on the organization of health care delivery, financial incentives, and
practice patterns.
• Different study designs (prospective, retrospective, models, expert opinion) render cross-
study comparisons hazardous.
• Some studies report data gathered on patients 10 years previously-it is likely that practice
patterns have changed, with regard to both surgical and endovascular techniques and to the
use of hospital wards.
For example, the question of primary amputation versus revascularization for patients with CLI
is difficult to answer, for a number of reasons. First, most of the studies were retrospective,
which precludes any valid conclusion. Even when patients are adjusted for severity, using, for
example, the American Society ofAnesthesiologists (ASA) scoring system, there could be a rea-
sonable suspicion that primary amputation is performed on sicker patients and that revascular-
ization is attempted when patients are healthier. Second, hospital costs are not sufficient to
make a comparison for diseases that impose a major burden on society.26 Third, authors com-
paring the costs of revascularizations with those ofprimary amputations report diverging results
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on which is more expensive. It appears that both are within the range of $20,000 to $30,000
(Euro18,600-27,900) for uncomplicated patients. When follow-up costs are included, an extra
$20,000 is added yearly for both revascularization and amputation.F Fourth, comorbid condi-
tions are inadequately reported by most authors, even though they have a major influence on
costs. Using the University of California at Los Angeles (UCLA) data, it can be estimated that
comorbid conditions or complications double the hospital cost.28 Fifth, a related issue is the dis-
tinction between primary and secondary amputation, which is not always made clear by authors.
As mentioned, the hospital cost of a secondary amputation is usually twice the cost of a primary
amputation. Sixth, authors do not always identify clearly the stage and type of occlusion, which
constitute important cost drivers. A meta-analysis comparing angioplasty and surgery for
patients with claudication and CLI reported that the hazard rate ratios for these procedures
were 2.0 and 1.9, respectively, which means that when a patient undergoes any type ofrevascu-
larization at the later stage of CLI, the risks of failure and secondary amputation are doublcd.J?
Similarly, it is unclear that an unadjusted comparison between the costs of surgical revasculariza-
tion and balloon angioplasty is valid, because the type of arterial disease may differ. As found by
Hunink et al,14 PTA was undertaken in patients with less severe disease than is seen in surgical
revascularization patients (See Section D).
Costs for primary PTA are roughly 25% lower than costs for primary bypass but increase dra-
matically over bypass costs when major complications or failure requiring re-do procedures are
included. The costs for initial PTA were $11,000 (Euro 10,230) without complication, but
when a repeat or additional procedure was required, the costs increased to $33,000 (Euro
30,690) and increased up to $51,000 (Euro 47,430) when the complication resulted in an
amputation. Thus, it appears that, in addition to reducing length of stay (and using endovascu-
lar techniques), the best approach to cost-effectiveness is the selection of patients according to
probability of success in the revascularization method chosen.26
The Role of Decision Modeling and Meta-analysis
Although the randomized controlled trial (RCT) is considered the ideal study design to evaluate
efficacy of a new treatment, performing such a trial is not always feasible because of practical or
ethical reasons. Furthermore, the results of RCTs cannot always be generalized, because of the
restricted inclusion of patients and the specific circumstances in which patients are treated. In
addition, the outcomes measured in RCTs usually have a limited time frame, whereas for deci-
sion-making purposes outcomes over a longer time frame ideally should be considered. Finally,
when evaluating diagnostic tests, randomizing patients across all possible sequences and logical
combinations of tests would require an enormous sample size.
Alternative methods for the evaluation of tests and treatments are meta-analysis and decision
modeling. A meta-analysis is a systematic review and quantitative analysis of the results of previ-
ous studies. A meta-analysis involves performing a careful search for all published studies and
preferably also those unpublished. Criteria need to be defined and used to determine which
studies are included and which excluded. Using analytical methods designed to adjust for differ-
ences in case mix, one can quantitatively pool the results and adjust for various factors that may
influence the results. 30,31,32 Using such techniques, the results from various cohort series evalu-
ating PTA, stent placement, and bypass surgery for PAD have been combined.29,33,34 The diag-
nostic performance of a test also may be systematically reviewed and summarized with a meta-
analysis. The data regarding diagnostic tests are best combined in a summary receiver operating
characteristic (SROC) curve, which adjusts for the different positivity criteria used by various
authors.3S An example has been published in the area of PAD, which metaanalyzes the results of
Duplex Doppler.V'
Decision analysis can be used to evaluate the tradeoffs relevant to a decision by mathematically
modeling the risks, effectiveness, and costs of all potential strategies.37,38,39A theoretical model
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integrates all of the available evidence and analyzes which diagnostic or therapeutic strategy
optimizes the management under varying assumptions. Analyses considering therapeutic options
for PAD would, for example, need to consider variables such as procedural mortality and mor-
bidity, patency results, and quality of life as function of a patent vessel.13,40 Comparing treat-
ments such as exercise training and revascularization involves modeling the effect of the treat-
ment in avoiding the development of contralateral symptoms, which can require a very complex
decision model.U An analysis comparing diagnostic tests such as MRA and angiography would
need to include the prior probability of PAD, data on the diagnostic performance ofMRA com-
pared with angiography, the foregone QALY owing to missing PAD or not identifying the opti-
mal procedure (false negative), the negative effect on quality-adjusted life years owing to incor-
rectly labeling someone as having PAD or performing the wrong procedure (false positive), and
the costs of diagnosis and treatment.f- Using decision models, one can determine the optimal
sequence oftests and the positivity criteria (optimal operating points) on the receiver operating
characteristic curves of each test.
Every model has some uncertainty associated 'with it. To analyze this uncertainty, one can use
sensitivity analysis. With sensitivity analysis, one evaluates the effect of varying assumptions and
determines under what conditions and for which threshold values a particular test or treatment
appears cost-effective. If many variables are uncertain, one can perform a Monte Carlo simula-
tion, in which multiple runs of the model are performed, each time drawing values for the
uncertain variables at random from their corresponding distribution. The resulting distribution
of outcomes (typically costs and effectiveness) represents the uncertainty in the results. Using
such simulation experiments, one can simulate a clinical trial before actually performing it,
which can help focus the research question and pinpoints the information that needs to be col-
lected during the trial. Examples of such simulation experiments exist in the area of PAD.41,43
Ideally, clinical trials and modeling studies are used to complement each other. A meta-analysis
and decision model can be used initially to summarize the available information, explore the
potential usefulness of alternative strategies, and identify crucial variables that need to be esti-
mated. Subsequently, based on the decision model, one can choose the two most relevant
strategies and compare these in a randomized controlled clinical trial in which only short- and
mid-term costs and health benefits are measured. Finally, the lifetime costs and benefits can sub-
sequently be estimated using me decision model with inputs based on the clinical trial.
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